Millipore Sigma Vibrant Logo

OP20 Anti-c-Abl (Ab-3) Mouse mAb (24-21)

Overview

Replacement Information

Key Specifications Table

Species ReactivityHostAntibody Type
H, MMMonoclonal Antibody

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
OP20-100UG
Retrieving availability...
Limited Availability
Limited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Plastic ampoule 100 μg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewRecognizes the ~145 kDa human c-Abl, the ~150 kDa mouse c-Abl, v-Abl, and the Bcr/Abl translocation products in ALL (~190 kDa) and CML (~210 kDa). Does not inhibit protein tyrosine kinase activity.
    • Antibody Target Gene Symbol: ABL1
    • Target Synonym: ABL, AI325092, bcr/abl, C-ABL, C-ABL 1B, CABL1, E430008G22Rik, JTK7, MGC117749, p145Abl, p150, v-abl
    • Entrez Gene Name: c-abl oncogene 1, receptor tyrosine kinase
    • Hu Entrez ID: 25 (Related Antibodies: PK1006 PK1013 OP19)
    • Mu Entrez ID: 11350
    • Rat Entrez ID: 311860
    • Catalogue NumberOP20
      Brand Family Calbiochem®
      SynonymsAnti-Abl, Anti-p150
      References
      ReferencesWiedemann, L.M., et al. 1988. Blood 71, 349.
      Stam, K., et al. 1985. N. Engl. J. Med. 313, 1429.
      Konopka, J.B., et al. 1984. Cell 37, 1035.
      Prywes, R., et al. 1983. Cell 34, 569.
      de Klein, A., et al. 1982. Nature 300, 765.
      Reynolds, F.H., Jr., et al. 1980. J. Virol. 36, 374.
      Reynolds, F.H., Jr., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 3974.
      Witte, O.N., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 2488.
      Abelson, H.T. and Rabstein, L.S. 1970. Cancer Res. 30, 2213.
      Product Information
      FormLiquid
      FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin, pH 7.5.
      Positive controlK562 (human bcr/abl), HL-60 (normal abl), and ANN-1 (murine abl) cells
      Preservative≤0.1% sodium azide
      Quality LevelMQ100
      Applications
      Application ReferencesOriginal Clone Schiff-Maker, L., et al. 1986. J. Virol. 57, 1182. Immunofluorescence Schiff-Maker, L. and Rosenberg, N. 1986. Virol. 154, 286.
      Key Applications Immunoblotting (Western Blotting)
      Immunofluorescence
      Immunoprecipitation
      Not Neutralization Studies
      Application NotesImmunoblotting (1-5 µg/ml)
      Immunofluorescence (see application references)
      Immunoprecipitation (1-2 µg/sample)
      Neutralization Studies (not recommended)
      Application CommentsDoes not inhibit protein tyrosine kinase activity. Detects human c-Abl (145 kDa), mouse c-Abl (150 kDa), v-Abl, and the Bcr/Abl translocation products in ALL (~210 kDa) and CML (~190 kDa). HL-60 and NIH3T3 cells contain normal, non-rearranged protein. Antibody should be titrated for optimal results in individual sample types.
      Biological Information
      Immunogena recombinant protein consisting of the carboxyl region of v-abl protein fused to TrpE
      Clone24-21
      HostMouse
      IsotypeIgG₁
      Species Reactivity
      • Human
      • Mouse
      Antibody TypeMonoclonal Antibody
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Yes
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalog Number GTIN
      OP20-100UG 04055977208900

      Documentation

      Anti-c-Abl (Ab-3) Mouse mAb (24-21) Certificates of Analysis

      TitleLot Number
      OP20

      References

      Reference overview
      Wiedemann, L.M., et al. 1988. Blood 71, 349.
      Stam, K., et al. 1985. N. Engl. J. Med. 313, 1429.
      Konopka, J.B., et al. 1984. Cell 37, 1035.
      Prywes, R., et al. 1983. Cell 34, 569.
      de Klein, A., et al. 1982. Nature 300, 765.
      Reynolds, F.H., Jr., et al. 1980. J. Virol. 36, 374.
      Reynolds, F.H., Jr., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 3974.
      Witte, O.N., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 2488.
      Abelson, H.T. and Rabstein, L.S. 1970. Cancer Res. 30, 2213.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision02-October-2007 RFH
      SynonymsAnti-Abl, Anti-p150
      ApplicationImmunoblotting (1-5 µg/ml)
      Immunofluorescence (see application references)
      Immunoprecipitation (1-2 µg/sample)
      Neutralization Studies (not recommended)
      DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with p.3U1 mouse myeloma cells (see application references). Recognizes the v-Abl, the ~145-150 kDa c-Abl, the ~210 kDa Bcr-Abl (CML), and the ~190 kDa Bcr-Abl (ALL) proteins.
      BackgroundThe abl oncogene was initially identified as the viral transforming gene (v abl) of Abelson murine leukemia virus (A-MuLV), from a chemically thymectomized mouse inoculated with Moloney murine leukemia virus (M MuLV). The v-abl genome consists of M-MuLV gag sequences fused to mouse c-abl, resulting in the production of phosphoproteins, p160 and p120 gag/c-abl with protein-tyrosine kinase activity, as the major translational products. The abl oncogene is implicated in several human leukemias including 90-95% of chronic myelocytic (CML), 20-25% of adult acute lymphoblastic (ALL), and 2-5% of pediatric ALL. In these leukemias the c-abl proto-oncogene undergoes a chromosomal (9;22) translocation producing the Philadelphia (Ph1) chromosome resulting in the fusion of c-abl sequences to the bcr gene of chromosome 22. The molecular consequences of this translocation is the generation of a chimeric bcr/c-abl mRNA encoding activated abl protein-tyrosine kinase.
      HostMouse
      Immunogena recombinant protein consisting of the carboxyl region of v-abl protein fused to TrpE
      Clone24-21
      IsotypeIgG₁
      Specieshuman, mouse
      Positive controlK562 (human bcr/abl), HL-60 (normal abl), and ANN-1 (murine abl) cells
      FormLiquid
      FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin, pH 7.5.
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsDoes not inhibit protein tyrosine kinase activity. Detects human c-Abl (145 kDa), mouse c-Abl (150 kDa), v-Abl, and the Bcr/Abl translocation products in ALL (~210 kDa) and CML (~190 kDa). HL-60 and NIH3T3 cells contain normal, non-rearranged protein. Antibody should be titrated for optimal results in individual sample types.
      Storage +2°C to +8°C
      Do Not Freeze Yes
      Toxicity Standard Handling
      ReferencesWiedemann, L.M., et al. 1988. Blood 71, 349.
      Stam, K., et al. 1985. N. Engl. J. Med. 313, 1429.
      Konopka, J.B., et al. 1984. Cell 37, 1035.
      Prywes, R., et al. 1983. Cell 34, 569.
      de Klein, A., et al. 1982. Nature 300, 765.
      Reynolds, F.H., Jr., et al. 1980. J. Virol. 36, 374.
      Reynolds, F.H., Jr., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 3974.
      Witte, O.N., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 2488.
      Abelson, H.T. and Rabstein, L.S. 1970. Cancer Res. 30, 2213.
      Application referencesOriginal Clone Schiff-Maker, L., et al. 1986. J. Virol. 57, 1182. Immunofluorescence Schiff-Maker, L. and Rosenberg, N. 1986. Virol. 154, 286.